Elcatonin
From PeptidePlaza, the free peptide reference · Entry #1107 · Nootropic · Sources fetched 2026-09-11 · Editorial standards
Elcatonin (also known as Elcatonina, Elcatonine, Elcatoninum, (Aminosuberic acid 1,7)-eel calcitonin) is a nootropic research peptide. Elcatonin is a synthetic calcitonin analog derived from eel calcitonin, currently in Phase 2 clinical trials for parathyroid diseases.
Elcatonin is a synthetic research peptide that mimics the action of calcitonin, a hormone involved in calcium regulation. It is a modified form of eel calcitonin, specifically (Aminosuberic acid 1,7)-eel calcitonin. Research into elcatonin has explored its potential applications, including its efficacy and safety in postmenopausal women with osteoporosis. Studies have also investigated its vasodilator effects on retinal blood vessels. Elcatonin is currently in Phase 2 clinical trials for the treatment of parathyroid diseases, indicating ongoing investigation into its therapeutic utility.
1 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
1.1 Indicated / studied for
- Parathyroid Diseases
2 Chemical and physical properties
| CAS number | 60731-46-6 |
|---|---|
| Molar mass | 3363.8 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
3 Research studies (8)
- Salmon calcitonin reduces oxaliplatin-induced cold and mechanical allodynia in rats
Biological & pharmaceutical bulletin (2013) - Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019) · Systematic Review - Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors
Clinical cancer research : an official journal of the American Association for Cancer Research (2005) - [Guidelines for drug therapy of postmenopausal osteoporosis]
Wiener medizinische Wochenschrift (1946) (2002) · Review - Vasodilator Effects of Elcatonin, a Synthetic Eel Calcitonin, on Retinal Blood Vessels in Rats
Biological & pharmaceutical bulletin (2015) - Possible involvement of descending serotonergic systems in antinociception by centrally administered elcatonin in mice
Biological & pharmaceutical bulletin (1999) - Hypercalcemia Associated with Extramammary Paget's Disease
Case reports in oncology (2020) · Case Series - Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys
Journal of bone and mineral metabolism (2009)
4 Safety and risk profile
4.1 Regulatory status
Elcatonin is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
5 Frequently asked questions
- What is Elcatonin?
- Elcatonin is a synthetic analog of calcitonin, specifically derived from eel calcitonin. It is a research peptide that has been investigated for its role in calcium regulation and potential therapeutic applications.
- What is Elcatonin used for?
- Elcatonin is currently in Phase 2 clinical trials for parathyroid diseases. It has also been studied for its potential efficacy in postmenopausal women with osteoporosis and its vasodilator effects on retinal blood vessels.
- What is Elcatonin derived from?
- Elcatonin is a synthetic peptide that is derived from eel calcitonin, with a specific modification at aminosuberic acid 1,7.
- What is the regulatory status of Elcatonin?
- Elcatonin is currently in Phase 2 clinical trials for parathyroid diseases, indicating that it is undergoing further investigation for its therapeutic potential.
6 References
- Elcatonin — compound summary PubChem. View source
- Elcatonin — molecule record ChEMBL. View source
- Elcatonin — published literature (151 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Elcatonin.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also nootropic
A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Also nootropic
A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).
Also nootropic
Eptifibatide is an integrin alpha-IIb/beta-3 inhibitor used to decrease the rate of death or myocardial infarction in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention.